Narcolepsy Market

DelveInsight’s ‘Narcolepsy–Market Insights, Epidemiology, and Market Forecast-2030’ report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of Narcolepsy in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


The Narcolepsy market report provides analysis regarding current treatment practices, marketed drugs like Provigil, Xyrem, JZP-258, JZP-110 etc., emerging therapies like FT-218, AXS-12 and other promising candidates like SUVN-G3031, TAK-994, TAK-925, market share of the individual therapies, and historical, current and forecasted Narcolepsy market size from 2017 to 2030, segmented by seven major markets.


The report also covers current Narcolepsy treatment practice/algorithm, guidelines, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.


Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017–2030


Narcolepsy – Disease Understanding and Treatment Algorithm

Overview:

Narcolepsy is a chronic neurological/brain disorder which involves poor control of sleep and wakefulness. Narcolepsy is classically a tetrad of symptoms including EDS, cataplexy, sleep paralysis, and hypnagogic hallucinations. People suffering from narcolepsy experience periods of excessive daytime sleepiness and sudden uncontrollable episodes of falling asleep during any time of the day.


According to ICSD-III(International Classification of Sleep Disorders-third edition), Narcolepsy is classified as distinct central nervous system hypersomnia in narcolepsy type 1 (NT1), formerly Narcolepsy with cataplexy caused by a selective loss of hypothalamic neurons producing hypocretin, and narcolepsy type 2 (NT2), formerly Narcolepsy without cataplexy and with normal hypocretin levels.


Narcolepsy can be diagnosed by using several tests and techniques such as physical examination, exhaustive medical history and tests that are considered essential in confirming a diagnosis of Narcolepsy are the polysomnogram (PSG) and the multiple sleep latency test.

Treatment:

There is no curative therapy for Narcolepsy till date, and current recommended therapies in Narcolepsy are limited to symptomatic treatment, targeting the main symptoms of the disease, depending on their severity. Behavioral and psychosocial interventions also impact the clinical outcomes of patients significantly. Various therapies have been approved by the USFDA and EMA as first and second-line treatment options for Narcolepsy.


This chapter covers the details of conventional and current medical therapies available for the treatment of Narcolepsy. It also provides Narcolepsy treatment guidelines across the United States and Europe.


DelveInsight’s Narcolepsy market report gives a thorough understanding of the disease by including details such as disease definition, etiology, types, neurobiology, biomarkers and diagnosis. It also provides Narcolepsy treatment pattern and treatment guidelines in the US and Europe.


Epidemiology:

The Narcolepsy epidemiology chapters provide insights about historical and current Narcolepsy patient pool and forecasted trends for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Narcolepsy epidemiology is segmented by the diagnosed prevalent cases of Narcolepsy, subtype-specific cases of Narcolepsy, clinical manifestations associated with Narcolepsy and age-group wise prevalence of Narcolepsy. Besides, the report includes a thorough analysis of all segments.


According to DelveInsight’s, the total prevalent population of Narcolepsy in seven major markets was 499,888 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017–2030).


Among all the seven major markets, total prevalent cases for Narcolepsy were highest in Japan, followed by the United States and Germany. France accounted for the least number of prevalent cases among the 7MM.


Drug Chapters:

This segment encloses the detailed analysis of the drugs in the Narcolepsy pipeline. It also helps understand the Narcolepsy clinical trial details, expressive pharmacological action, agreements of the included drug, and the latest news and press releases.


The first-line care of a patient with SCI involves securing the airway, breathing, and circulation, followed by appropriate spinal immobilization in the field to limit further insult of the highly susceptible cord during transport. Emerging therapies like MC001, AST-OPC1, KP-100IT, Elezanumab and Stemirac are expected to bring a positive shift to the overall market.


Market Outlook:

The market size of Narcolepsy is expected to increase at a significant CAGR during the study period (2017–2030). Among all the seven major markets, the United States accounted for the largest Narcolepsy market size. Among the EU5 countries, Germany had the largest market size, with USD 131.90 million, followed by the United Kingdom with USD 87.93 million in 2017. Italy had the smallest market size of Narcolepsy, with USD 14.66 million in 2017.


Drugs Uptake:

This section focuses on the rate of uptake of the potential drugs in the Narcolepsy market or expected to get launched in the market during the study period 2017–2030. The analysis covers Narcolepsy market uptake by drugs; patient uptake by therapies; and sale of each drug.


It helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size. All of which will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


The dynamics of Narcolepsy market is anticipated to experience a major positive shift in the coming years owing to the expected launch of therapies like FT-218 and AXS-12.


Narcolepsy: Pipeline Development Activities

The report provides insights into different therapeutic candidates and also analyses the key players involved in developing targeted therapeutics.


Pipeline Development Activities:

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details, and emerging therapies, concerning Narcolepsy.


KOL Views

To keep up with current market trends, we take KOLs and SME’s opinion working in Narcolepsy domain through primary research to fill the data gaps and validate our secondary research. It will support the clients in assessing potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.


Competitive Intelligence Analysis

We have performed the competitive and market Intelligence analysis of the Narcolepsy Market by using various competitive intelligence tools that include SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. Besides, the inclusion of the analysis entirely depends upon the data availability.


Report Highlights:

  • In the coming years, Narcolepsy market scenario is expected to experience a positive shift across the 7MM due to a robust pipeline.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase II and Phase III), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities


Narcolepsy Report Insights:

  • Patient Population
  • Therapeutic Approaches
  • Narcolepsy Pipeline Analysis
  • Narcolepsy Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies


Narcolepsy Report Key Strengths:

  • 11 years Forecast
  • 7MM Coverage
  • Narcolepsy Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake



Narcolepsy Report Assessment:

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers


Key Questions

Market Insights:

  • What was the Narcolepsy market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Narcolepsy total market size as well as market size by therapies across the 7MM during the forecast period (2017–2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Narcolepsy market size during the forecast period (2017–2030)?
  • At what CAGR, the Narcolepsy market is expected to grow in 7MM during the forecast period (2017–2030)?
  • What would be the Narcolepsy market outlook across the 7MM during the forecast period (2017–2030)?
  • What would be the Narcolepsy market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What are the disease risk, burden and unmet needs of Narcolepsy?
  • What is the historical Narcolepsy patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Narcolepsy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population pertaining to Narcolepsy?
  • Out of all 7MM countries, which country would have the highest prevalent population of Narcolepsy during the forecast period (2017–2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017–2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for Narcolepsy treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Narcolepsy in the USA, Europe, and Japan?
  • How many companies are developing therapies for the treatment of Narcolepsy?
  • How many therapies are developed by each company for Narcolepsy?
  • How many are emerging therapies in mid-stage, and late stage of development for Narcolepsy treatment?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Narcolepsy therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Narcolepsy and their status?
  • What are the key designations that have been granted for the emerging therapies for Narcolepsy?
  • What is the global historical and forecasted market of Narcolepsy?


Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Narcolepsy market
  • To understand the future market competition in the Narcolepsy market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Narcolepsy in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Narcolepsy market
  • To understand the future market competition in the Narcolepsy market


Which geography accounted for the largest Narcolepsy market size?

The United States accounted for the largest Narcolepsy market size.


What is forecasted Narcolepsy size in 2030?

DelveInsight estimates an increase in Narcolepsy Market Size during the study period, 2017–2030


What are the present Narcolepsy market drivers?

Shortcomings associated with existing treatment, active clinical pipeline, increasing prevalence of disease


What are the Narcolepsy market barriers?

Need for better treatment practices, Hurdles in treatment selection, Identification of initial symptoms


How many companies are developing drugs for Narcolepsy?

Currently, two key pharma players are developing the drug for Narcolepsy  


Which are the leading companies in Narcolepsy market?

Key Players – Avadel Pharmaceuticals, Axsome Therapeutics


How is epidemiology segmented for Narcolepsy?

Diagnosed prevalent cases of Narcolepsy, subtype-specific cases of Narcolepsy, clinical manifestations associated with Narcolepsy and age-group wise prevalence of Narcolepsy

1 Key Insights

2 Executive Summary of Narcolepsy

3 SWOT Analysis for Narcolepsy

4 Narcolepsy Epidemiology Overview at a Glance

4.1 Patient Share (%) Distribution of Narcolepsy in 2017

4.2 Patient Share (%) Distribution of Narcolepsy in 2030

5 Narcolepsy Market Overview at a Glance

5.1 Market Share (%) Distribution of Narcolepsy in 2017

5.2 Market Share (%) Distribution of Narcolepsy in 2030

6 Disease Background and Overview: Narcolepsy

6.1 Introduction

6.2 Signs and Symptoms

6.3 Complications

6.4 Pathophysiology

6.5 Etiology

6.6 Risk Factors

6.7 Diagnosis

7 Epidemiology and Patient Population

7.1 Key Findings

7.2 Population and Forecast Parameters

8 7MM Total Prevalent Patient Population of Narcolepsy

8.1 The United States

8.1.1 Diagnosed Prevalent Patient Population of Narcolepsy in the United States

8.1.2 Subtype-specific cases of Narcolepsy in the United States

8.1.3 Clinical Manifestations associated with Narcolepsy

8.1.4 Age-group wise Prevalence of Narcolepsy

8.2 Germany

8.2.1 Diagnosed Prevalent Patient Population of Narcolepsy in Germany

8.2.2 Subtype-specific cases of Narcolepsy in Germany

8.2.3 Clinical Manifestations associated with Narcolepsy

8.2.4 Age-group wise Prevalence of Narcolepsy

8.3 France

8.3.1 Diagnosed Prevalent Patient Population of Narcolepsy in France

8.3.2 Subtype-specific cases of Narcolepsy in France

8.3.3 Clinical Manifestations associated with Narcolepsy

8.3.4 Age-group wise Prevalence of Narcolepsy

8.4 Italy

8.4.1 Diagnosed Prevalent Patient Population of Narcolepsy in Italy

8.4.2 Subtype-specific cases of Narcolepsy in Italy

8.4.3 Clinical Manifestations associated with Narcolepsy

8.4.4 Age-group wise Prevalence of Narcolepsy

8.5 Spain

8.5.1 Diagnosed Prevalent Patient Population of Narcolepsy in Spain

8.5.2 Subtype-specific cases of Narcolepsy in Spain

8.5.3 Clinical Manifestations associated with Narcolepsy

8.5.4 Age-group wise Prevalence of Narcolepsy

8.6 United Kingdom

8.6.1 Diagnosed Prevalent Patient Population of Narcolepsy in the United Kingdom

8.6.2 Subtype-specific cases of Narcolepsy in the United Kingdom

8.6.3 Clinical Manifestations associated with Narcolepsy

8.6.4 Age-group wise Prevalence of Narcolepsy

8.7 Japan

8.7.1 Diagnosed Prevalent Patient Population of Narcolepsy in Japan

8.7.2 Subtype-specific cases of Narcolepsy in Japan

8.7.3 Clinical Manifestations associated with Narcolepsy

8.7.4 Age-group wise Prevalence of Narcolepsy

9 Treatment and Management

9.1 Guideline and Management

9.1.1 American Academy of Sleep Medicine Guidelines

9.1.2 European Federation of Neurological Societies (EFNS) Guidelines

10 Unmet Needs

11 Marketed Products

11.1 Provogil: Cephalon Inc.

11.1.1 Drug Description

11.1.2 Regulatory Milestones

11.1.3 Product Profile

11.2 Xyrem: Jazz Pharmaceuticals

11.2.1 Product Description

11.2.2 Regulatory Milestones

11.2.3 Advantages and Disadvantages

11.2.4 Product Profile

11.3 JZP-258: Jazz Pharmaceuticals Inc.

11.3.1 Drug Description

11.3.2 Regulatory Milestones

11.3.3 Clinical Development

11.3.6 Product Profile

11.4 JZP-110: Jazz Pharmaceuticals

11.4.1 Product Description

11.4.2 Regulatory Milestones

11.4.3 Product Profile

12 Other Narcoleptics

12.1 Anafranil (clomipramine)

12.1.1 Product Description

12.1.2 Regulatory Milestones

12.1.3 Advantages and Disadvantages

12.2 Desipramine

12.2.1 Product Description

12.2.2 Regulatory Milestones

12.2.3 Advantages and Disadvantages

12.2.4 Product Profile

12.3 Prozac (Fluoxetine)

12.3.1 Product Description

12.3.2 Regulatory Milestones

12.3.3 Advantages and Disadvantages

12.3.4 Product Profile

12.4 Tofranil (Imipramine)

12.4.1 Product Description

12.4.2 Advantages and Disadvantages

12.4.3 Product Profile

12.5 Vivactil (Protriptyline)

12.5.1 Product Description

12.5.2 Regulatory Milestones

12.5.3 Advantages and Disadvantages

12.5.4 Product Profile

12.6 Zoloft (Sertraline)

12.6.1 Product Description

12.6.2 Regulatory Milestones

12.6.3 Advantages and Disadvantages

12.6.4 Product Profile

12.7 Effexor (Venlafaxine)

12.7.1 Product Description

12.7.2 Regulatory Milestones

12.7.3 Advantages and Disadvantages

12.7.4 Product Profile

12.8 Desoxyn (Methamphetamine)

12.8.1 Product Description

12.8.2 Regulatory Milestones

12.8.3 Advantages and Disadvantages

12.8.4 Product Profile

12.9 NUVIGIL

12.9.1 Product Description

12.9.2 Regulatory Milestones

12.9.3 Advantages and Disadvantages

12.9.4 Product Profile

12.1 Wakix (Pitolisant)

12.10.1 Product Description

12.10.2 Regulatory Milestones

12.10.3 Advantages and Disadvantages

12.10.4 Product Profile

12.11 Ritalin

12.11.1 Product Description

12.11.2 Regulatory Milestones

12.11.3 Advantages and Disadvantages

12.11.4 Product Profile

12.12 Dexedrine

12.12.1 Product Description

12.12.2 Regulatory Milestones

12.12.3 Advantages and Disadvantages

12.12.4 Product Profile

12.13 Adderall

12.13.1 Product Description

12.13.2 Regulatory Milestones

12.13.3 Advantages and Disadvantages

12.13.4 Product Profile

12.14 Atomoxetine

12.14.1 Product Description

12.14.2 Regulatory Milestones

12.14.3 Advantages and Disadvantages

12.14.4 Product Profile

13 Emerging Drugs

13.1 Sodium oxybate ER: Avadel Pharmaceuticals

13.1.1 Product Description

13.1.2 Regulatory Milestones

13.1.3 Clinical Development

13.1.4 Safety and efficacy

13.1.5 Product Profile

13.2 AXS-12 (Reboxetine): Axsome Therapeutics

13.2.1 Product Description

13.2.2 Regulatory Milestones

13.2.3 Clinical Development

13.2.4 Safety and efficacy

13.2.5 Product Profile

14 Other Promising Candidates

14.1 SUVN-G3031: Suven Life Sciences Limited

14.1.1 Product description

14.1.2 Clinical Development

14.1.3 Safety and Efficacy

14.2 TAK-994: Takeda

14.2.1 Product description

14.2.2 Clinical Development

14.3 TAK-925: Takeda

14.3.1 Product Description

14.3.2 Clinical Development

14.3.3 Safety and Efficacy

14.4 ADAIR: Vallon Pharmaceuticals

14.4.1 Product Description

14.4.2 Clinical Development

14.4.3 Safety and Efficacy

14.5 Mazindol CR: NLS Pharma

14.5.1 Product Description

14.5.2 Product Development Activities

14.5.3 Product Profile

15 No Development Reported

15.1 BTD – 001: Balance Therapeutics

15.1.1 Product Description

15.1.2 Clinical Development

15.1.3 Clinical Trial Information

15.1.4 Product Profile

15.2 TS-091: Taisho Pharmaceutical Co

15.2.1 Product Description

15.2.2 Clinical Development

15.2.3 Product Profile

15.3 THN102 (Modafinil + Flecainide): Theranexus

15.3.1 Regulatory Milestones

15.3.2 Clinical Development

15.3.3 Clinical Trial Information

15.3.4 Product Profile

16 Narcolepsy: 7 Major Market Analysis

16.1 Key Findings

16.2 Market Size of Narcolepsy in 7MM

17 7MM: Narcolepsy Market Outlook

18 Country-wise Market Analysis

18.1 The United States

18.1.1 Total Market size of Narcolepsy in the U.S.

18.1.2 Therapy-based market size of Narcolepsy in the U.S.

18.2 EU-5 Countries

18.2.1 Germany

18.2.2 France

18.2.3 Italy

18.2.4 Spain

18.2.5 United Kingdom

18.3 Japan

18.3.1 Total Market size of Narcolepsy in Japan

18.3.2 Therapy-based market size of Narcolepsy in Japan

19 Market Drivers

20 Market Barriers

21 Appendix

21.1 Report Methodology

22 DelveInsight Capabilities

23 Disclaimer

24 About DelveInsight

List of Table

Table 1: Summary of Narcolepsy, Epidemiology, and Key Events (2017–2030)

Table 2:Total Prevalent Patient Population of Narcolepsy in the 7MM (2017–2030)

Table 3: Prevalent Cases of Narcolepsy in the United States (2017–2030)

Table 4: Subtype-specific cases of Narcolepsy in the United States (2017–2030)

Table 5: Clinical Manifestations associated with Narcolepsy in the United States (2017–2030)

Table 6: Age-group wise Prevalence of Narcolepsy (2017–2030)

Table 7: Prevalent Cases of Narcolepsy in Germany (2017–2030)

Table 8: Subtype-specific cases of Narcolepsy in Germany (2017–2030)

Table 9:Clinical Manifestations associated with Narcolepsy in Germany (2017–2030)

Table 10: Age-group wise Prevalence of Narcolepsy (2017–2030)

Table 11: Prevalent Cases of Narcolepsy in France (2017–2030)

Table 12: Subtype-specific cases of Narcolepsy in France (2017–2030)

Table 13: Clinical Manifestations associated with Narcolepsy in France (2017–2030)

Table 14: Age-group wise Prevalence of Narcolepsy (2017–2030)

Table 15: Prevalent Cases of Narcolepsy in Italy (2017–2030)

Table 16:Subtype-specific cases of Narcolepsy in Italy (2017–2030)

Table 17: Clinical Manifestations associated with Narcolepsy in Italy (2017–2030)

Table 18: Age-group wise Prevalence of Narcolepsy (2017–2030)

Table 19: Prevalent Cases of Narcolepsy in Spain (2017–2030)

Table 20: Subtype-specific cases of Narcolepsy in Spain (2017–2030)

Table 21: Clinical Manifestations associated with Narcolepsy in Spain (2017–2030)

Table 22: Age-group wise Prevalence of Narcolepsy (2017–2030)

Table 23: Prevalent Cases of Narcolepsy in the United Kingdom (2017–2030)

Table 24:Subtype-specific cases of Narcolepsy in the United Kingdom (2017–2030)

Table 25: Clinical Manifestations associated with Narcolepsy in the United Kingdom (2017–2030)

Table 26: Age-group wise Prevalence of Narcolepsy (2017–2030)

Table 27: Prevalent Cases of Narcolepsy in Japan (2017–2030)

Table 28: Subtype-specific cases of Narcolepsy in Japan (2017–2030)

Table 29: Clinical Manifestations associated with Narcolepsy in Japan (2017–2030)

Table 30: Age-group wise Prevalence of Narcolepsy in Japan (2017–2030)

Table 31: Sodium oxybate, Clinical Trial Description

Table 32: AXS-12, Clinical Trial Description

Table 33: BTD-001 Clinical Trial Description

Table 34: TS-091 Clinical Trial Description

Table 35: THN102 Clinical Trial Description

Table 36: 7 Major Market Size of Narcolepsy in USD million (2017–2030)

Table 37: Market Size of Narcolepsy in the United States, USD million (2017–2030)

Table 38: Therapy-based Market Size of Narcolepsy in the US, in USD million (2017–2030))

Table 39: Market Size of Narcolepsy in Germany, in USD million (2017–2030)

Table 40: Therapy-based Market Size of Narcolepsy in Germany, in USD million (2017–2030))

Table 41: Market Size of Narcolepsy in France, in USD million (2017–2030)

Table 42: Therapy-based Market Size of Narcolepsy in France, in USD million (2017–2030)

Table 43: Market Size of Narcolepsy in Italy, in USD million (2017–2030)

Table 44: Therapy-based Market Size of Narcolepsy in Italy, in USD million (2017–2030))

Table 45: Market Size of Narcolepsy in Spain, in USD million (2017–2030)

Table 46: Therapy-based Market Size of Narcolepsy in Spain, in USD million (2017–2030))

Table 47: Market Size of Narcolepsy in the UK, in USD million (2017–2030)

Table 48: Therapy-based Market Size of Narcolepsy in the UK, in USD million (2017–2030))

Table 49: Market Size of Narcolepsy in Japan, in USD million (2017–2030)

Table 50: Therapy-based Market Size of Narcolepsy in in Japan, in USD million (2017–2030)

List of Figures

Figure 1: SWOT Analysis

Figure 2: Complications of Narcolepsy

Figure 3: Pathophysiology of Narcolepsy

Figure 4: Prevalent Cases of Narcolepsy in the 7MM (2017–2030)

Figure 5: Diagnosed Prevalent Cases of Narcolepsy in the United States (2017–2030)

Figure 6: Subtype-specific cases of Narcolepsy in the United States (2017–2030)

Figure 7: Clinical Manifestations associated with Narcolepsy in the United States (2017–2030)

Figure 8: Age-group wise Prevalence of Narcolepsy (2017–2030)

Figure 9: Diagnosed Prevalent Cases of Narcolepsy in Germany (2017–2030)

Figure 10: Subtype-specific cases of Narcolepsy in Germany (2017–2030)

Figure 11: Clinical Manifestations associated with Narcolepsy in Germany (2017–2030)

Figure 12: Age-group wise Prevalence of Narcolepsy (2017–2030)

Figure 13: Diagnosed Prevalent Cases of Narcolepsy in France (2017–2030)

Figure 14: Subtype-specific cases of Narcolepsy in France (2017–2030)

Figure 15: Clinical Manifestations associated with Narcolepsy in France (2017–2030)

Figure 16: Age-group wise Prevalence of Narcolepsy (2017–2030)

Figure 17: Diagnosed Prevalent Cases of Narcolepsy in Italy (2017–2030)

Figure 18: Subtype-specific cases of Narcolepsy in Italy (2017–2030)

Figure 19: Clinical Manifestations associated with Narcolepsy in Italy (2017–2030)

Figure 20: Age-group wise Prevalence of Narcolepsy (2017–2030)

Figure 21: Diagnosed Prevalent Cases of Narcolepsy in Spain (2017–2030)

Figure 22: Subtype-specific cases of Narcolepsy in Spain (2017–2030)

Figure 23: Clinical Manifestations associated with Narcolepsy in Spain (2017–2030)

Figure 24: Age-group wise Prevalence of Narcolepsy (2017–2030)

Figure 25: Diagnosed Prevalent Cases of Narcolepsy in the United Kingdom (2017–2030)

Figure 26: Subtype-specific cases of Narcolepsy in the United Kingdom (2017–2030)

Figure 27: Clinical Manifestations associated with Narcolepsy in the United Kingdom (2017–2030)

Figure 28: Age-group wise Prevalence of Narcolepsy (2017–2030)

Figure 29: Diagnosed Prevalent Cases of Narcolepsy in Japan (2017–2030)

Figure 30: Subtype-specific cases of Narcolepsy in Japan (2017–2030)

Figure 31: Clinical Manifestations associated with Narcolepsy in Japan (2017–2030)

Figure 32: Age-group wise Prevalence of Narcolepsy (2017–2030)

Figure 33: Decision tree for starting and then adapting the therapy for excessive daytime sleepiness and cataplexy

Table 34: Therapies for the treatment of Excessive daytime sleepiness and irresistible episodes of sleep with Narcolepsy

Figure 35: Non pharmacological treatment practices for Narcolepsy

Figure 36: Unmet Needs for Narcolepsy

Figure 37: 7 Major Market Size of Narcolepsy in USD million (2017–2030)

Figure 38: Market Size of Narcolepsy in the US, in USD million (2017–2030)

Figure 39: Therapy-based Market Size of Narcolepsy in the US, in USD million (2017–2030)

Figure 40: Market Size of Narcolepsy in Germany, USD millions (2017–2030)

Figure 41: Therapy-based Market Size of Narcolepsy in Germany, in USD million (2017–2030)

Figure 42: Market Size of Narcolepsy in France, in USD million (2017–2030)

Figure 43: Therapy-based Market Size of Narcolepsy in France, in USD million (2017–2030)

Figure 44: Market Size of Narcolepsy in Italy, in USD million (2017–2030)

Figure 45: Therapy-based Market Size of Narcolepsy in Italy, in USD million (2017–2030)

Figure 46: Market Size of Narcolepsy in Spain, in USD million (2017–2030)

Figure 47: Therapy-based Market Size of Narcolepsy in Spain, in USD million (2017–2030)

Figure 48: Market Size of Narcolepsy in the UK, USD millions (2017–2030)

Figure 49: Therapy-based Market Size of Narcolepsy in the UK, in USD million (2017–2030)

Figure 50: Market Size of Narcolepsy in Japan, in USD million (2017–2030)

Figure 51: Therapy-based Market Size of Narcolepsy in Japan, in USD million (2017–2030)

Figure 52: Market Drivers

Figure 53:Market Barriers

Cephalon Inc.

Jazz Pharmaceuticals

  • Tags:
  • Narcolepsy market
  • Narcolepsy market research
  • Narcolepsy market insight
  • Narcolepsy market trends
  • Narcolepsy market forecast
  • Narcolepsy market share
  • Narcolepsy pipeline drugs
  • Narcolepsy treatment algorithm
  • Narcolepsy drugs
  • Narcolepsy sales forecasting
  • Narcolepsy market size
  • Narcolepsy disease
  • Narcolepsy epidemiology
  • Narcolepsy

Forward to Friend

Need A Quote